BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:OncoVerity\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies OncoVerity\, Inc.'s drugs run\, f
 rom ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06384261-3085@assetmemo.bio
DTSTAMP:20261121T005733Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Cusatuzumab: Phase 2 readout est. (NCT06384261)
DESCRIPTION:Cusatuzumab\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Study
  Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and A
 zacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy\nEstima
 ted primary completion: January 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/cusatuzumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06384261
URL:https://assetmemo.bio/drug/cusatuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
